Marksans Pharma Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 3/6

Marksans Pharma ist ein dividendenzahlendes Unternehmen mit einer aktuellen Rendite von 0.19%, die durch die Erträge gut gedeckt ist.

Wichtige Informationen

0.2%

Dividendenausschüttung

0.05%

Rückkaufsrendite

Gesamte Aktionärsrendite0.2%
Zukünftige Dividendenrendite1.1%
Wachstum der Dividende5.0%
Nächster Dividendenzahlungsterminn/a
Ex-Dividendendatumn/a
Dividende pro Aktie₹0.600
Ausschüttungsquote9%

Jüngste Updates zu Dividenden und Rückkäufen

Recent updates

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Oct 24
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Sep 21
Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Jul 28
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

May 31
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Feb 16
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

Jan 26
Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Dec 02
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Jun 21
Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Nov 17
Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Sep 16
This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Sep 01
Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Jun 14
Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

May 27
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Feb 19
Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 04
Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Jan 20
Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Jan 05
Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%

Dec 21
Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%

What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?

Dec 06
What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: MARKSANSDie Dividendenzahlungen des Unternehmens waren in den vergangenen 10 Jahren volatil.

Wachsende Dividende: MARKSANSDie Dividendenzahlungen des Unternehmens sind in den letzten 10 Jahren gestiegen.


Dividendenrendite im Vergleich zum Markt

Marksans Pharma Dividendenrendite im Vergleich zum Markt
Wie sieht die Dividendenrendite von MARKSANS im Vergleich zum Markt aus?
SegmentDividendenrendite
Unternehmen (MARKSANS)0.2%
Untere 25 % des Marktes (IN)0.3%
Markt Top 25 % (IN)1.1%
Branchendurchschnitt (Pharmaceuticals)0.7%
Analystenprognose (MARKSANS) (bis zu 3 Jahre)1.1%

Bemerkenswerte Dividende: MARKSANSDie Dividende des Unternehmens (0.19%) ist im Vergleich zu den unteren 25 % der Dividendenzahler auf dem Markt Indian (0.25%) nicht bemerkenswert.

Hohe Dividende: MARKSANSDie Dividende des Unternehmens (0.19%) ist im Vergleich zu den besten 25% der Dividendenzahler auf dem Markt Indian (1.14%) niedrig.


Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Mit ihrer niedrigen Ausschüttungsquote (8.7%) sind die Dividendenzahlungen von MARKSANS durch die Erträge vollständig gedeckt.


Barausschüttung an die Aktionäre

Cashflow-Deckung: Mit einer angemessenen Ausschüttungsquote (52.3%) sind die Dividendenzahlungen von MARKSANS durch den Cashflow gedeckt.


Entdecken Sie dividendenstarke Unternehmen